

## VACCINES VS TOTAL AMR R&D INVESTMENT


### FUNDING

898 million USD

7% of total funding

3 times less than Therapeutics

\$0.7 for every \$10 invested in AMR R&D



## FUNDERS

90%


US - 50%

EU - 17%

DK - 13%

UK - 10%

74% of funding for AMR vaccines comes from top 5 funders



## INSTITUTION TYPES


### FUNDING

38% for universities

31% for public institutions

12% for SMEs

Almost 70% of funding goes to universities and public institutions; only 12% to SMEs



## INFECTIOUS AGENTS & DISEASES

48%


5% Critical

15% High

28% Medium

3% TARGETS ANTIFUNGALS

49% IS TARGETED TOWARDS SPECIFIC DISEASES




33% of funding for AMR therapeutics is targeted towards WHO bacterial priority pathogens

Others: Virus, Parasites, Not specified & not applicable pathogens  
STIs: Sexually transmissible infections | SsTIs: Skin and soft tissue infections | UTIs: Urinary tract Infections | RTIs: Respiratory tract Infections | TB: Tuberculosis

## SECTORS

The majority of investments target human health

Cross-sectoral projects that span two or more sectors make up only 1.2% funding for AMR vaccines R&D



## GAPS

## OPPORTUNITIES

## RECOMMENDATIONS

### TARGET PRIORITY PATHOGENS

Increase support for R&D targeting priority pathogens of all types, including antifungals

### SET TARGETS

Establish targets for AMR R&D based on priority needs

### FUNDING PARTNERSHIPS

Focus on developing funding partnerships to create diversity in funding streams

### EVALUATION & ASSESSMENT

Further evaluation of the link between investment in AMR vaccines and impact on the pipeline of products is needed

### R&D ALIGNMENT

Align R&D of therapeutics, diagnostics, and vaccines targeting the same pathogens and/or diseases

### DEVELOPMENT

Increase support for development of vaccines across the full One Health spectrum

## Want to know more?

globalamrhub@dzif.de

<https://globalamrhub.org/>

Global AMR R&D Hub

GlobalAMRHub

